Exclusive global license agreement for first in class macroencapsulation device
We are very happy to announce a global exclusive license with Brigham and Women's Hospital for the first in class convection-enhanced macroencapsulation device (ceMED) developed by Dr Jeff Karp and his team, in collaboration with the Harvard Stem Cell Institute,...
We are grateful to Innovation Fund Denmark for awarding an Innobooster grant to PanCryos. The grant will co-fund our ongoing effort to develop a curative stem cell-based therapy for type 1 diabetes together with our fantastic collaboration partners.
300 Years of Leadership and Innovation
Delighted to have Pancryos featured in the official History of Parliament Trust 300 Years of Leadership and Innovation commemorative album, celebrating leadership and pioneering businesses that are spearheading innovative healthcare products.
PanCryos “Ones to watch”
Pancryos selected as "Ones to watch" by Nature Research Awards' Spinoff Prize. See complete list of The 2021 One to Watch (nature.com)
Licensing agreement with Takara Bio Europe AB
Takara Bio Europe AB and PanCryos announce licensing agreement to enable development of cell-based therapy for diabetes. We are excited to announce that Takara Bio Europe AB will be supporting PanCryos' efforts to develop a cell-based therapy for diabetes through the...
Dr. Jonathan Lakey joins Pancryos Scientific Advisory Board team
We are delighted to announce that Dr. Jonathan Lakey has joined Pancryos Scientific Advisory Board team. Dr. Lakey is an internationally recognized expert in the field of diabetes and islet transplantation and has received numerous awards for his groundbreaking...
Dr Jeff Karp is joining Pancryos Scientific Advisory Board team as Chairman
We are very excited to announce that Dr Jeff Karp is joining Pancryos Scientific Advisory Board team as Chairman. He is a world leading problem solver in the fields of drug delivery, medical devices, stem cell therapeutics, and tissue adhesives. Dr Karp has received...
Jacqueline Ameri droppede prestigefyldt forskerjob for iværksætteri. I dag kæmper hun for at kurere diabetes
Siden 2014 har forsker Jacqueline Ameri været CEO i Pancryos, der arbejder på at få en særlig celleterapi på markedet. Danmark er ikke god nok til at udnytte det potentiale, der er i forskermiljøet, mener Cepos. Read more here.
Biotekhåb satser på at kurere diabetes
Biotekselskabet Pancryos fra København arbejder på en celleterapi, der skal kunne kurere type 1-diabetes. Folkene bag mener at have opdaget en fremgangsmåde, der kan overgå konkurrenterne på området. Read more here.
Fra forsker til CEO
For fem år siden sprang Jacqueline Ameri ud som iværksætter og takkede nej til egen forskergruppe. I dag er virksomheden netop blevet optaget i det prestigefyldte Creation House-program, hvor de har fået et lån på 10 mio. kr. fra Novo Nordisk Fonden. Read more...